A pharmaceutical composition for use in the prevention and treatment of hypertension caused by renin, aldosteronism, adrenoleukodystrophy, glomerulosclerosis, proteinuria, nephropathy, hepatic steatosis, hypertriglyceridemia, or hyperreninemia, caused by excessive expression or excessive activity of an alpha receptor Liver X (LXR), wherein the pharmaceutical composition contains as an effective component a compound represented by the following Formula 1, a pharmaceutically acceptable salt thereof, a solvate thereof, or a hydrate thereof: ** Formula ** wherein X is carbon or nitrogen, Q is sulfur, oxygen, or -S>； = O, and R1 and R2 are each independently selected from the group consisting of a hydrogen atom, C1-C7 alkyl, C3-C7 cycloalkyl, C1 haloalkyl -C7, C1-C7 alkoxy, C3-C7 cycloalkoxy, (C1-C7) alkyl thio, C3-C7 cycloalkyl, thio, C1-C7 alkenyl, C1-C7 alkynyl, C1-C7 sulfonyl, (C1-C7) alkyl aminocarbonyl, HO-C1-C7 alkyl, HS-alq C1-C7 uyl, hydroxy, thiol, halogen, carboxyl, nitro, cyano, C1-C7 carbonyl), (C1-C7) alkoxy, carbonyl (C1-C7) carbonyloxy, (C1-C4) alkyl, C1-C4 alkyl, C1-C4 alkoxy C1-C4 alkyl, C1-C4 alkyl C1-C4 thioalkyl, amino, C1-C7 alkyl amino, C1-C7 alkyl carbonylamino, C1-C4 alkoxy -C4) amino, (C1-C4) alkyl thioalkyl (C1-C4) amino, (C1-C4) alkyl sulfonylamino, phenyl, heteroaryl, phenylalkyl C1-C4, heteroarylalkyl C1-C4, phenylalkoxy (C1-C4) alkyl C1- C4, phenylalkyl (C1-C4) thioalkyl C1-C4, phenoxyalkyl C1-C4, phenylthioalkyl C1-C4, phenylcarbonylamino, phenoxyalkyl (C1-C4) carbonylamino, phenylalkoxy (C1-C4) alkyl (C1-C4) carbonylamino, heteroaryloxyalkyl C1- C4, heteroarylthioalkyl C1-C4, and heteroarylalkyl (C1-C4) thioalkyl C1-C4, wherein the heteroaryl refers to a cyclic compound of 5 or 6 members containing at least one heteroatom selected from the group consisting of nitrogen, sulfur and oxygen； the phenyl and heteroaryl is substituted or unsubstituted and an available substituent is selected from the group consisting of halogen, C1-C7 alkyl, C
